Keyphrases
National Cohort Study
100%
Type 2 Diabetic Patients
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Bullous Pemphigoid
100%
Hazard Ratio
66%
Patients with Diabetes
33%
Insulin
22%
Dipeptidyl peptidase-4 (DPP-4)
22%
Risk-adjusted
11%
Multivariate Analysis
11%
Risk Factors
11%
Comorbidity
11%
Confidence Interval
11%
Epilepsy
11%
Adjusted Hazard Ratio
11%
Diabetic Patients
11%
Diabetes Duration
11%
Low Risk
11%
Renal Disease
11%
Taiwan National Health Insurance Research Database
11%
Significant Risk Factors
11%
Incremental Risk
11%
Cerebrovascular Disease
11%
Cumulative Incidence
11%
Potential Confounders
11%
Antidiabetic Agents
11%
Competing Mortality
11%
Medicine and Dentistry
Cohort Analysis
100%
Patient with Type 2 Diabetes
100%
Bullous Pemphigoid
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Hazard Ratio
77%
Patient with Diabetes
33%
Multivariate Analysis
11%
Diabetes
11%
Nephropathy
11%
Diabetes Mellitus
11%
Antidiabetic Agent
11%
Cerebrovascular Disease
11%
Cumulative Incidence
11%
Comorbidity
11%
Nursing and Health Professions
Cohort Analysis
100%
Patient with Type 2 Diabetes
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Bullous Pemphigoid
100%
Hazard Ratio
77%
Patient with Diabetes
33%
National Health Insurance
11%
Kidney Disease
11%
Confidence Interval
11%
Multivariate Analysis
11%
Diabetes Mellitus
11%
Cerebrovascular Disease
11%
Antidiabetic Agent
11%
Comorbidity
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Bullous Pemphigoid
100%
Non Insulin Dependent Diabetes Mellitus
100%
Kidney Disease
11%
Diabetes Mellitus
11%
Antidiabetic Agent
11%
Cerebrovascular Disease
11%
Comorbidity
11%